OncoTriage. Поиск наилучшего лечения для вашего пациента

Миелодисплазии

НОВАЯ СТАТЬЯ

Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study.

5-HT3RAs may prevent azacitidine-induced nausea and vomiting more effectively than metoclopramide.

DOI: 10.1186/s40780-025-00444-3

Wakasugi Y, Ikeda Y, Noda S, Murata M, Morita SY

Journal of pharmaceutical health care and sciences, 2025-04-26

Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment.

Prophylactic and pre-emptive donor lymphocyte infusion (pro/preDLI) is used to prevent haematological relapse of AML and MDS after allogeneic stem cell transplantation...

DOI: 10.3324/haematol.2024.287206

Velázquez GF, Weller JF, Rubeck A, Arndt T, Schiele S, Mezger M, Lengerke C, Bethge W, Trepel M, Müller G, Christopeit M, Schmid C

Haematologica, 2025-04-26

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.

Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear...

DOI: 10.1182/bloodadvances.2024014948

Ragaini S, Galli A, Genuardi E, Gandossini M, Alessandria B, Civita AM, Evangelista A, Amaducci E, Stefoni V, Cavallo F, Ballerini F, Puccini B, Vallisa D, Michieli M, Pascarella A, Palmas A, Patti C, Lucchini E, Careddu MG, Merli M, Postorino M, Boc

Blood advances, 2025-04-24

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH; NCT04558918) and C5i-naive (APPOINT-PNH; NCT04820530) patients with paroxysmal nocturnal hemoglobinuria (PNH)...

DOI: 10.1182/bloodadvances.2024014652

Risitano AM, de Castro C, Han B, Kulasekararaj A, Maciejewski JP, Scheinberg P, Ueda Y, Vallow S, Bermann G, Dahlke M, Kumar R, Peffault de Latour R

Blood advances, 2025-04-24

Наверх

Миелодисплазии

Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study.

Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment.

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Свяжитесь с нами

Вход в аккаунт

Восстановление пароля